CardioToxicity of Implantation and defibrillation testing in TransvenoUs and Subcutaneous implantable defibrillators.

Published: 22-12-2015 Last updated: 19-04-2024

To compare acute cardiotoxicity, measured by Troponin difference pre- and postimplantation, induced by implantation and defibrillation testing of transvenous and subcutaneous ICDs.

| Ethical review | Approved WMO |
|-----------------------|------------------------|
| Status | Recruitment stopped |
| Health condition type | Cardiac arrhythmias |
| Study type | Observational invasive |

Summary

ID

NL-OMON47092

Source ToetsingOnline

Brief title TITUS Study

Condition

Cardiac arrhythmias

Synonym ICD implantation and defibrillation

Research involving Human

Sponsors and support

Primary sponsor: Academisch Medisch Centrum Source(s) of monetary or material Support: Ministerie van OC&W

1 - CardioToxicity of Implantation and defibrillation testing in TransvenoUs and Sub \dots 11-05-2025

Intervention

Keyword: Defibrillation, ICD

Outcome measures

Primary outcome

Delta troponin level pre versus post ICD implantation

Secondary outcome

Not applicable

Study description

Background summary

The new subcutaneous ICD requires more energy to meet the defibrillation requirements and may therefore cause more myocardial injury than the lower energy shocks from transvenous devices, but lacks an endocardial lead and may in that respect actually cause less myocardial injury. One previous animal study by Killingworth et al. compared cardiac enzyme release after implantation and five shocks at maximum output. Four pigs were implanted with a transvenous ICDs (35 Joules per shock) and four with a subcutaneous ICDs (65 Joules per shock). The interesting result from this study was that only in the transvenous ICD group the cardiac enzymes increased and in none of the pigs implanted with a subcutaneous ICD. This indicates that transvenous ICD implantation and testing causes myocardial injury, whether implantation and subsequent mandated device test of a subcutaneous ICD does not cause myocardial injury. However, no human data on cardiac injury after subcutaneous ICD implantation and testing has been published thus far.

Study objective

To compare acute cardiotoxicity, measured by Troponin difference pre- and post-implantation, induced by implantation and defibrillation testing of transvenous and subcutaneous ICDs.

Study design

This study is a prospective non-randomized comparison three study arms. - Arm A: 20 patients with de novo transvenous ICD implantation that subsequently undergo defibrillation threshold testing.

2 - CardioToxicity of Implantation and defibrillation testing in TransvenoUs and Sub ... 11-05-2025

- Arm B: 20 patients with transvenous ICD pulse generator replacement that subsequently undergo defibrillation threshold testing.

- Arm C: 20 patients with de novo subcutaneous ICD implantation that subsequently undergo defibrillation threshold testing.

- Arm D: 20 patients with de novo transveneus ICD implantation that do not undergo subsequent defibrillation testing.

Study burden and risks

Prior to the implantation of the ICD, a blood sample will be drawn from the intravenous line that is place as part of routine care. Six to eight hours after defibrillation threshold testing a second blood sample will be drawn from the IV-line.

Contacts

Public Academisch Medisch Centrum

Meibergdreef 9 Amsterdam 1105AZ NL **Scientific** Academisch Medisch Centrum

Meibergdreef 9 Amsterdam 1105AZ NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

3 - CardioToxicity of Implantation and defibrillation testing in TransvenoUs and Sub ... 11-05-2025

Inclusion criteria

Patients with an ICD indication, according to the European society of cardiology guidelines, who will undergo ICD implantation.

Exclusion criteria

- (Potential) pregnancy

Study design

Design

| Study type: Observational invasive | |
|------------------------------------|-------------------------|
| Masking: | Open (masking not used) |
| Control: | Uncontrolled |
| Primary purpose: | Treatment |

Recruitment

| NL | |
|---------------------------|---------------------|
| Recruitment status: | Recruitment stopped |
| Start date (anticipated): | 15-07-2016 |
| Enrollment: | 80 |
| Туре: | Actual |

Ethics review

| Approved WMO | |
|--------------------|--------------------|
| Date: | 22-12-2015 |
| Application type: | First submission |
| Review commission: | METC Amsterdam UMC |
| Approved WMO | |
| Date: | 22-03-2018 |
| Application type: | Amendment |

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

 Register
 ID

 CCMO
 NL55212.018.15